Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Business Wire
BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorderBayer explores opportunity to address high unmet medical need of patients suffering from AS and advances research efforts through close cooperation with AS patient organizationsDerived from the strategic research cooperation with Evotec, advancement of BAY 3401016 into ASSESS Phase IIa clinical study is further strengthening Bayer’s development portfolioThe program has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Study that said glyphosate herbicide is safe retracted 25 years after publication [Yahoo! Finance Canada]Yahoo! Finance Canada
- Taboo no more: Leaders gather to discuss women's health [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Trump administration backs Bayer as Roundup fight moves toward Supreme Court [FOX Business Network]FOX Business Network
- RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary EndpointsBusiness Wire
- Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating.MarketBeat